Profile: C R Bard Inc (BCR.N)

BCR.N on New York Stock Exchange

168.46USD
11:47am EST
Price Change (% chg)

$-0.64 (-0.38%)
Prev Close
$169.10
Open
$169.30
Day's High
$169.86
Day's Low
$168.46
Volume
7,243
Avg. Vol
127,152
52-wk High
$174.44
52-wk Low
$125.01

Search Stocks

C. R. Bard, Inc. (Bard), incorporated in 1923, is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. As of December 31, 2011, the Company sold a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The Company participates in the markets for vascular, urology, oncology and surgical specialty products. Bard also has a product group of other products. Through subsidiaries and a joint venture, Bard markets its products to customers in over 100 countries outside the United States. The Company’s principal international markets were in Europe and Japan as of December 31, 2011. On November 10, 2011, Bard acquired Medivance, Inc. On December 16, 2011, the Company acquired Lutonix, Inc.

Vascular Products

Bard’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. These products include percutaneous transluminal angioplasty (PTA) catheters, chronic total occlusions (CTO) catheters, guidewires, introducers and accessories; peripheral vascular stents and stent grafts, vena cava filters and biopsy devices; electrophysiology products, including electrophysiology laboratory systems and diagnostic, therapeutic and temporary pacing electrode catheters, and fabrics, meshes and implantable vascular grafts. Bard’s Conquest, Atlas and Dorado PTA catheters are used by clinicians for the treatment of arterial venous access stenosis and other PVDs.

The Company’s Ultraverse and VascuTrak PTA catheters and Crosser CTO catheter are the Company’s offerings in the small-vessel segment of the PVD market. Bard’s line of peripheral vascular stent and stent-graft devices includes the Flair AV (arterial venous) Access Stent Graft, EYLuminexx Iliac Stent, and the LifeStent family of stents approved for use in the superficial femoral and proximal popliteal arteries. Bard’s vena cava filters product line includes devices, which can be either permanently implanted or retrieved after the threat of blood clots traveling from the lower extremities to a patient’s lungs has passed. Bard’s Vacora and Finesse devices are used for the diagnosis of breast tumors. In July 2010, the Company acquired SenoRx, Inc., whose product portfolio includes products, such as the EnCor stereotactic-guided and MRI-guided breast biopsy systems, the Gel Mark line of breast tissue markers and the Contura brachytherapy catheter used in the treatment of breast cancer. With SenoRx, Bard offers products across percutaneous breast biopsy and marker segments, in addition to providing a therapeutic device for site-specific partial breast irradiation following lumpectomy procedures. In Europe, the Company sells its high-density Mesh Ablation Catheter for the diagnosis and treatment of atrial fibrillation.

Urology Products

Bard’s urology products include basic drainage products, continence products and urological specialty products. The Foley catheter is the Company product in the urology field. The company markets Foley catheters, including the infection control Foley catheter (Bardex I.C. Foley catheter) for the treatment of urinary tract infections. Other urology products include surgical slings used to treat stress urinary incontinence; fecal incontinence products; natural and synthetic devices for the treatment of pelvic floor and vaginal prolapse; brachytherapy services, devices and radioactive seeds used to treat prostate cancer; intermittent urinary drainage catheters, urine monitoring and collection systems; ureteral stents, and specialty devices for ureteroscopic procedures and stone removal. The Company also markets the line of StatLock catheter stabilization devices, which are used primarily to secure peripheral intravenous catheters. These devices are also used to secure many other types of catheters sold by Bard and other companies, including Foley catheters. Medivance, Inc.’s Arctic Sun system with the ArcticGel pads provides Targeted Temperature Management therapy to patients requiring therapeutic hypothermia.

Oncology Products

Bard’s oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. These include specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters and enteral feeding devices. The Company’s specialty vascular access products are used primarily for chemotherapy. The Company’s PowerPICC catheters and PowerPort devices can also be used to inject contrast media at high flow rates. Bard’s Site-Rite vascular access ultrasound device and Sherlock tip locator system help nurses place a peripherally inserted central catheters (PICC ) at a patient’s bedside. The Company’s Sapiens Tip Confirmation System can be used in place of x-rays to confirm proper placement of the PICC prior to treatment.

Surgical Specialty Products

Bard’s surgical specialty products include implanted patches and fixation systems for hernia and other soft tissue repairs, irrigation devices for orthopedic, laparoscopic and gynecological procedures and products for topical hemostasis. The Company’s soft tissue repair products consist primarily of hernia repair implants, including both synthetic and natural-tissue configurations, and hernia implant fixation devices. Within the hernia implants line, products such as Bard’s PerFix plug and 3D Max are used for inguinal (groin) hernia repair procedures. The Company also markets products for the repair of ventral (abdominal) hernias, including the Ventrio, Ventrio ST, Ventralex, Ventralex ST and Composix LP hernia patches. The Company also produces the ECHO PS Positioning System, which helps facilitate mesh deployment laparoscopically. Bard’s line of natural-tissue hernia products, including the Collamend FM and Allomax patches, are used to repair ventral hernias. In complex hernias, pre-existing infections or high risk of infection often preclude the use of synthetic mesh for the repair. The Company’s SorbaFix device is a bioresorbable-tack fixation device for use in laparoscopic and open surgical procedures. Its PermaFix product is a permanent anchor fixation device built on the SorbaFix platform.

Company Address

C R Bard Inc

730 Central Avenue
MURRAY HILL   NJ   07974
P: +1908.2778000
F: +1908.2778412

Search Stocks